Ascelia Pharma: Wrap up from latest event with CEO Magnus Corfitzen
CEO Magnus Corfitzen gave a thoroughly presentation of the company’s equity story.
Recently a review article was published on Orviglance in the respected scientific journal “Investigative Radiology”. Orviglance is addressing an unmet medical need, developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. The total addressable market (TAM) is USD 800m. Hereof is US around 50%. The CEO confirms the market size and expect a high market share due to best in class qualities and enhancement of existing treatments. Phase-3 read-out expected in May 2024 as earlier communicated to the market. Ascelia Pharma expect to file a US NDA soon after.
Oncoral (Chemotherapy) showed promising data in two Phase-1 studies, Oncoral is a low dosing daily administered tablet versus today’s treatment with intravenous high dosing every 3rd. week. Ascelia Pharma expect to file for Phase-2 proof-of-concept if finances allow in 2024.
Ascelia Pharma recently announced they secured finances until Q2-2025 with a minimum dilution for existing shareholders. The burn rate is significantly down from 2023.
View the event here: Ascelia Pharma event
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:00 AM 12-02-2024.
Ascelia Pharma
Ascelia Pharma er et svensk biotek selskab med fokus på behandling af sjældne kræftsygedomme. De udvikler og markedsfører nye lægemidler, hvor der er behov for bedre behandlingsmuligheder eller hvor der ikke findes muligheder for behandling i dag, og de har en klar go-to-market strategi. Ascelia Pharma har to kandidater i pipelinen, Orviglance og Oncoral. Orviglance er et nyt kontrastmiddel til MR-scanning, og udviklet til at forbedre opdagelsen og visualiseringen af fokale leverlæsioner(Inklusiv levermetastaser – og primære tumorer) hos patienter med nedsat lever funktion. Oncoral er en tablet med en potent anti-tumor effekt, der indtages på daglig basis. Oncoral har vist god effekt ved kræftformer der er svære at behandle, og en bedre virkning/bivirkningsprofil for patienten sammenlignet med intravenøs behandlinger med høj dose udført på et hospital. Ascelia Pharma er noteret på Nasdaq Small Cap Stockholm med ticker ACE.
Read more on company page